# 5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab

> **NCT07124884** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Federation Francophone de Cancerologie Digestive** · enrollment: 300 (estimated)

## Conditions studied

- Colorectal Carcinoma
- KRAS G12C Mutation
- Unresectable Colorectal Cancer

## Interventions

- **DRUG:** Administration of experimental treatment association (sotorasib, panitumumab 5FU)

## Key facts

- **NCT ID:** NCT07124884
- **Lead sponsor:** Federation Francophone de Cancerologie Digestive
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08-31
- **Primary completion:** 2030-06-30
- **Final completion:** 2030-12-30
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2025-08-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07124884

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07124884, "5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT07124884. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*